Ran-Hui Cha Selected Research

AST 120

1/2022	Effects of AST-120 on muscle health and quality of life in chronic kidney disease patients: results of RECOVERY study.
1/2022	Phase angle as a marker for muscle health and quality of life in patients with chronic kidney disease.
7/2019	Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease.
1/2018	Erratum: Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea [Volume 36, Issue 1, March 2017, Pages 68-78].
3/2017	Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea.
1/2017	Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease.
4/2016	A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ran-Hui Cha Research Topics

Disease

6	Chronic Renal Insufficiency 01/2022 - 12/2010
6	Disease Progression 07/2019 - 04/2016
4	Sarcopenia 01/2022 - 12/2021
3	Proteinuria 01/2017 - 01/2014
2	Inflammation (Inflammations) 12/2021 - 10/2019
2	Acute Kidney Injury (Acute Renal Failure) 03/2020 - 10/2017
2	Reperfusion Injury 01/2020 - 01/2019
1	Peritoneal Fibrosis 10/2019
1	Fibrosis (Cirrhosis) 10/2019
1	Diabetes Mellitus 07/2019
1	Hypoxia (Hypoxemia) 01/2019
1	Acute Generalized Exanthematous Pustulosis 02/2018
1	Acidosis 10/2017
1	Cardiovascular Diseases (Cardiovascular Disease) 05/2017
1	Infections 10/2016
1	Respiratory Insufficiency (Respiratory Failure) 04/2016
1	Necrosis 06/2015
1	HIV Infections (HIV Infection) 01/2014
1	Glomerulonephritis 01/2014
1	Purpura 01/2014
1	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2014
1	Hemorrhage 01/2014
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2014
1	Chronic Kidney Failure (Chronic Renal Failure) 09/2011
1	Genetic Predisposition to Disease (Genetic Predisposition) 02/2011
1	IGA Glomerulonephritis (IGA Nephropathy) 01/2011

Drug/Important Bio-Agent (IBA)

7	AST 120IBA 01/2022 - 04/2016
2	SaltsIBA 03/2020 - 10/2017
2	Saline SolutionIBA 03/2020 - 10/2017
2	SolutionsIBA 03/2020 - 10/2017
2	CreatinineIBA 07/2019 - 04/2016
2	Hemoglobins (Hemoglobin)IBA 07/2019 - 01/2017
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 05/2017 - 01/2014
2	Biomarkers (Surrogate Marker)IBA 05/2017 - 01/2014
1	IndicanIBA 01/2022
1	Chemokine ReceptorsIBA 01/2020
1	Dialysis SolutionsIBA 10/2019
1	Fibronectins (Fibronectin)IBA 10/2019
1	Glucose (Dextrose)FDA LinkGeneric 10/2019
1	renalaseIBA 07/2019
1	EstersIBA 01/2019
1	caffeic acidIBA 01/2019
1	Interleukin-17 (Interleukin 17)IBA 01/2019
1	Janus Kinase 2IBA 01/2019
1	Interleukin-17 ReceptorsIBA 01/2019
1	HematinicsIBA 02/2018
1	C-Reactive ProteinIBA 01/2017
1	Viral RNAIBA 10/2016
1	Indicators and Reagents (Reagents)IBA 10/2016
1	OxalatesIBA 06/2015
1	SteroidsIBA 01/2014
1	Immunoglobulin A (IgA)IBA 01/2014
1	2-toluenesulfonamide (OTS)IBA 09/2011
1	Angiotensin IIIBA 01/2011
1	EnzymesIBA 01/2011
1	Cystatin CIBA 12/2010

Therapy/Procedure

2	Renal Dialysis (Hemodialysis) 12/2021 - 12/2021
2	Kidney Transplantation 09/2011 - 02/2011
1	Nutritional Support (Artificial Feeding) 12/2021
1	Peritoneal Dialysis 10/2019
1	Mechanical Ventilators (Ventilator) 04/2016
1	Art Therapy 01/2014
1	Transplantation 02/2011